A Phase II, Open-Label, Single-Arm Study to Assess the Efficacy and Safety of Decapeptyl SR (3 mg and 11.25 mg formulations) when administered by subcutaneous injection.

Trial Profile

A Phase II, Open-Label, Single-Arm Study to Assess the Efficacy and Safety of Decapeptyl SR (3 mg and 11.25 mg formulations) when administered by subcutaneous injection.

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Sep 2016

At a glance

  • Drugs Triptorelin (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms DISC
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 Jul 2012 Status changed from active, no longer recruiting to completed as reported by UKCRN.
    • 31 May 2012 Location (England) added as reported by United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top